Statin use vs. average non-HDL cholesterol levels in Slovakia

Slovakia: Statin use vs. average non-HDL cholesterol levels was 3.6 in 2018. ▼ Falling

Latest (2018)
3.6
Change on year
unchanged
World rank
30th
of 191 countries
All-time high
4.1
in 1983
All-time low
3.6
in 2012
Years of data
39
1980–2018

Statin use vs. average non-HDL cholesterol levels in Slovakia, 1980–2018

012341980199920181980: 41981: 41982: 41983: 4.11984: 4.11985: 4.11986: 4.11987: 4.11988: 4.11989: 4.11990: 4.11991: 4.11992: 4.11993: 4.11994: 41995: 41996: 41997: 41998: 41999: 3.92000: 3.92001: 3.92002: 3.82003: 3.82004: 3.82005: 3.82006: 3.72007: 3.72008: 3.72009: 3.72010: 3.72011: 3.72012: 3.62013: 3.62014: 3.62015: 3.62016: 3.62017: 3.62018: 3.6

Source: World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data.

Analysis

In 2018, statin use vs. average non-hdl cholesterol levels in Slovakia stood at 3.6. That is the lowest value across all 39 years on record.

Compared with earlier readings it is down 2.7% over ten years.

Over the whole period, statin use vs. average non-hdl cholesterol levels in Slovakia peaked at 4.1 in 1983 and was at its lowest, 3.6, in 2012.

Slovakia ranks 30th of 191 countries on this measure, in the top quarter.

The long-run direction has been consistently falling across the 39 years of available data.

Averages by decade

DecadeAverage LowestHighest Years
1980s 4.07 4 4.1 10
1990s 4.03 3.9 4.1 10
2000s 3.78 3.7 3.9 10
2010s 3.62 3.6 3.7 9

Countries ranked near Slovakia

  1. 30 Albania 3.6 compare
  2. 30 Andorra 3.6 compare
  3. 30 Austria 3.6 compare
  4. 30 Bulgaria 3.6 compare
  5. 30 Dominican Republic 3.6 compare
  6. 30 Estonia 3.6 compare
  7. 30 Hungary 3.6 compare
  8. 30 Indonesia 3.6 compare
  9. 30 Jamaica 3.6 compare
  10. 30 Jordan 3.6 compare
  11. 30 Montenegro 3.6 compare
  12. 30 North Macedonia 3.6 compare
  13. 30 Papua New Guinea 3.6 compare
  14. 30 Portugal 3.6 compare
  15. 30 Romania 3.6 compare
  16. 30 Russia 3.6 compare
  17. 30 Slovenia 3.6 compare
  18. 30 Ukraine 3.6 compare
  19. 30 Uruguay 3.6 compare
  20. 30 Uzbekistan 3.6 compare
  21. 30 Vanuatu 3.6 compare

See the full ranking of 191 places →

More reference data data for Slovakia

All data for Slovakia →

Frequently asked questions

What is statin use vs. average non-hdl cholesterol levels in Slovakia?
Statin use vs. average non-hdl cholesterol levels in Slovakia was 3.6 in 2018, according to World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data.
What is the highest statin use vs. average non-hdl cholesterol levels recorded in Slovakia?
The highest recorded value was 4.1 in 1983.
What is the lowest statin use vs. average non-hdl cholesterol levels recorded in Slovakia?
The lowest recorded value was 3.6 in 2012.
How does Slovakia rank for statin use vs. average non-hdl cholesterol levels?
Slovakia ranks 30th out of 191 countries with data for 2018.
Is statin use vs. average non-hdl cholesterol levels rising or falling in Slovakia?
Over the last ten years it is down 2.7%. The long-run trend across the full record is falling.
Where does this Slovakia data come from?
The figures come from World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as part of Statin use vs. average non-HDL cholesterol levels. Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 39 observations, free to reuse under CC BY 4.0 (Our World in Data).

About this data

Indicator
Statin use vs. average non-HDL cholesterol levels
Source
World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data
Licence
CC BY 4.0 (Our World in Data)
Coverage
191 places, 7,449 data points, 1980–2018
Last refreshed

The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.